Browsing by Author "Kocaman, Ayse Sagduyu"

Now showing 1 - 5 of 5

Assessment of Early Cognitive Impairment in Patients with Clinically Isolated Syndromes and Multiple Sclerosis
(HINDAWI LTD, 2014-01-01) Kirac, Leyla Baysal; Ekmekci, Ozgul; Yuceyar, Nur; Kocaman, Ayse Sagduyu
Objective. The aim of our study was to investigate the frequency and pattern of cognitive impairment in patients with clinically isolated syndromes and definite diagnosis of multiple sclerosis within the last 2 years. Methods. We assessed the cognitive status of 46 patients aged 18-49 years with clinically isolated syndromes or definite diagnosis of multiple sclerosis who have onset of their symptoms within the last 2 years. Patients were matched with 40 healthy participants for age, sex, and educational level. Neuropsychological assessment was performed by stroop test, paced auditory serial addition test (PASAT), controlled oral word association test (COWAT), clock drawing test, trail making test (TMT), faces symbol test (FST). Hamilton Depression Scale and Modified Fatigue Impact Scale were used to quantify the severity of any depression and fatigue the subjects might suffer. Results. 19.6\% of early MS/CIS group failed at 4 and more tests and had significant cognitive impairment focused on attention, executive functions, memory, and learning. No significant relationship was found between cognitive impairment and disability and fatigue scores. Discussion. Cognitive impairment can be present from the earliest stage of multiple sclerosis. It should be considered among the main manifestations of MS even in the earliest stages of the disease.
Botulinum Toxin in Migraine Treatment
(TURKISH NEUROPSYCHIATRY ASSOC-TURK NOROPSIKIYATRI DERNEGI, 2013-01-01) Aydinlar, Elif Ilgaz; Dikmen, Pinar Yalinay; Kocaman, Ayse Sagduyu
Since botulinum toxin might have a therapeutic effect on pain, many studies investigating the efficiency of botulinum toxin in headache treatment have been done. The most satisfying results were achieved by botulinum toxin type A (BoNT/A) in the treatment of chronic migraine. In this paper, we reviewed the clinical effectiveness of BoNT/A in migraine and included our clinical experience. In our ongoing pilot study, where we have repeated BoNT/A injections every 12 weeks, The difference in the Migraine Disability Assessment (MIDAS) scores between the first and the second injections was 61.1\%
OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study
(SPRINGEROPEN, 2017-01-01) Aydinlar, Elif Ilgaz; Dikmen, Pinar Yalinay; Kosak, Seda; Kocaman, Ayse Sagduyu
Background: OnabotulinumtoxinA (OnabotA) is considered effective in in patients with chronic migraine (CM) who failed on traditional therapies. This study was designed to evaluate the effect of OnabotA injection series on migraine outcome, negative emotional states and sleep quality in patients with CM. Methods: A total of 190 patients with CM (mean (SD) age: 39.3 (10.2) years
The COVID-19 from Neurological Overview
(GALENOS PUBL HOUSE, 2020-01-01) Acar, Turkan; Demirel, Esra Aciman; Afsar, Nazire; Akcali, Aylin; Demir, Gulsen Akman; Alagoz, Aybala Neslihan; Mengi, Tugce Angin; Arsava, Ethem Murat; Ayta, Semih; Bebek, Nerses; Bilgic, Basar; Boz, Cavit; Cakar, Arman; Celebisoy, Nese; Cevik, Mehmet Ugur; Delen, Firuze; Tekce, Hacer Durmus; Ekmekci, Hakan; Elmali, Ayse Deniz; Erdinc, Oguz Osman; Erdogan, Fusun Ferda; Eren, Fettah; Ergun, Ufuk; Parman, Yesim Gulsen; Gumus, Haluk; Algin, Demet Ilhan; Karabudak, Rana; Karadas, Omer; Yildiz, Ozlem Kayim; Koc, Emine Rabia; Adapinar, Demet Ozbabalik; Ozdemir, Atilla Ozcan; Ozturk, Serefnur; Kocaman, Ayse Sagduyu; Sahin, Sevki; Topcuoglu, Esen Saka; Sener, Ozden; Tezer, F. Irsel; Togrol, Rifat Erdem; Tokcaer, Ayse Bora; Topcuoglu, Mehmet Akif; Tuncer, Nese; Uca, Ali Ulvi; Uluc, Kayihan; Yaka, Erdem; Yon, Mehmet Ilker
Transient cortical blindness in COVID-19 pneumonia
(ELSEVIER, 2020-01-01) Kaya, Yildiz; Kara, Simay; Akinci, Canan; Kocaman, Ayse Sagduyu